Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Through Thick & Thin: Updates in Scleroderma

Jason Liebowitz, MD, FACR  |  January 22, 2025

Among the newer treatments for ILD in SSc are nintedanib, an antifibrotic agent, and tocilizumab, an inhibitor of interleukin (IL) 6. In the SENSCIS study, 576 patients with SSc-related ILD were randomly assigned to receive 150 mg of nintedanib by mouth twice daily or placebo. The primary end point was annual rate of decline in forced vital capacity (FVC) assessed over 52 weeks. Although patients in both arms of the study saw decline in the FVC, this decrease was less in the nintedanib group compared with the placebo group.6

In the focuSSced trial, more than 200 patients with diffuse cutaneous SSc were randomly assigned to receive 162 mg of subcutaneous tocilizumab or placebo weekly for 48 weeks. In this study, the primary skin fibrosis end point was not met, but findings for the secondary end point of FVC% predicted indicated that tocilizumab may preserve lung function in people with early SSc-ILD who also have elevated acute-phase reactants.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Based on these results, the FDA approved tocilizumab for the treatment of SSc-ILD, and this medication is now part of the pantheon of treatments for patients.

In Sum

Although no panacea for treatment of the condition exists, more can be done for patients than in years past.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Jason Liebowitz, MD, is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, New York.

References

  1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747–1765.
  2. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: A potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010 Jan;37(1):98–104.
  3. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618–3731.
  4. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655–2666.
  5. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–719.
  6. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518–2528.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Sclerosis Tagged with:interstitial lung disease (ILD)pulmonary hypertensionRaynaud’s phenomenonSclerodermaSSc-ILDsystemic sclerosis (SSc)

Related Articles

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

    Capillaroscopy a Safe and Direct Method for SSc Diagnosis

    June 13, 2011

    Seeing vessels clearly can help with discovery and timely treatment

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences